XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Product revenues $ 858 $ 467 $ 2,249 $ 2,027
Cost of product revenues 322 181 918 992
Amortization of intangible assets 306 306 919 919
Gross profit (loss) 230 (20) 412 116
Development revenues:        
Government contracts and other 454 1,306 2,270 2,856
Total development revenues 454 1,306 2,270 2,856
Operating expenses:        
Research and development 1,916 3,004 6,366 9,284
Sales and marketing 453 840 1,656 3,043
General and administrative 1,486 1,785 5,199 6,012
Change in fair value of warrants (1,676)   (1,676) 0
Total operating expenses 2,179 5,629 11,545 20,025
Operating loss (1,495) (4,343) (8,863) (17,053)
Other income (expense):        
Interest income 11 5 30 24
Interest expense (512) (474) (1,379) (1,603)
Other income (expense), net 9 5 157 233
Issuance costs of warrants (343)   (343) 0
Total other expense (835) (464) (1,535) (1,346)
Net loss (2,330) (4,807) (10,398) (18,399)
Beneficial conversion feature for convertible preferred stock (2,487)   (2,487)  
Net loss allocable to common stockholders $ (4,817) $ (4,807) $ (12,885) $ (18,399)
Basic and diluted net loss per share attributable to common stockholders $ (0.55) $ (1.39) $ (1.85) $ (6.22)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 8,716,194 3,449,083 6,972,615 2,956,403
Comprehensive loss:        
Net loss $ (2,330) $ (4,807) $ (10,398) $ (18,399)
Other comprehensive loss – foreign currency translation adjustments (55) 16 (205) (59)
Comprehensive loss $ (2,385) $ (4,791) (10,603) (18,458)
Assets Purchased from Azaya Therapeutics, Inc. [Member]        
Operating expenses:        
In process research and development acquired from Azaya Therapeutics     $ 0 $ 1,686